- Home
- APP vs REGN Comparison
APP vs REGN Comparison
Compare APP & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APP
- REGN
- Stock Information
- Founded
- APP 2012
- REGN 1988
- Country
- APP United States
- REGN United States
- Employees
- APP N/A
- REGN N/A
- Industry
- APP EDP Services
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- APP Technology
- REGN Health Care
- Exchange
- APP Nasdaq
- REGN Nasdaq
- Market Cap
- APP 116.4B
- REGN 110.0B
- IPO Year
- APP 2021
- REGN 1991
- Fundamental
- Price
- APP $342.34
- REGN $681.58
- Analyst Decision
- APP Buy
- REGN Buy
- Analyst Count
- APP 20
- REGN 25
- Target Price
- APP $304.89
- REGN $1,024.28
- AVG Volume (30 Days)
- APP 4.0M
- REGN 857.0K
- Earning Date
- APP 02-12-2025
- REGN 02-04-2025
- Dividend Yield
- APP N/A
- REGN N/A
- EPS Growth
- APP 1098.41
- REGN 15.31
- EPS
- APP 3.31
- REGN 40.43
- Revenue
- APP $4,289,729,999.00
- REGN $13,847,100,000.00
- Revenue This Year
- APP $41.33
- REGN $10.24
- Revenue Next Year
- APP $22.48
- REGN $4.30
- P/E Ratio
- APP $103.48
- REGN $16.86
- Revenue Growth
- APP 41.48
- REGN 5.72
- 52 Week Low
- APP $40.71
- REGN $666.25
- 52 Week High
- APP $417.64
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- APP 55.37
- REGN 36.27
- Support Level
- APP $307.07
- REGN $666.25
- Resistance Level
- APP $362.45
- REGN $743.28
- Average True Range (ATR)
- APP 16.82
- REGN 19.76
- MACD
- APP -2.16
- REGN 0.45
- Stochastic Oscillator
- APP 63.69
- REGN 19.90
About APP Applovin Corporation
AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).